Status:
COMPLETED
NAFLD Among Patients With Type 2 Diabetes and CKD
Lead Sponsor:
Rigshospitalet, Denmark
Conditions:
Non-Alcoholic Fatty Liver Disease
Chronic Kidney Diseases
Eligibility:
All Genders
18-90 years
Brief Summary
Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in developed countries affecting approximately 30 % of the general adult population. It represents an importa...
Detailed Description
INTRODUCTION Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in developed countries affecting approximately 30 % of the general adult population. The diseas...
Eligibility Criteria
Inclusion
- INCLUSION CRITERIA:
- Diagnosed type 2-diabetes
- eGFR \> 60 ml/ min/ 1,73 m2 with absence of proteinuria (N=54) OR eGFR \< 60 ml/ min/ 1,73 m2 (N=54)
- Outpatient at the department of endocrinology at either Rigshospitalet, Herlev Hospital, Gentofte Hospital or Steno Diabetes Center Copenhagen OR Outpatient at the department of nephrology at either Rigshospitalet or Herlev Hospital
- EXCLUSION CRITERIA
- End stage liver disease as diagnosed by MELD (model for end stage liver disease) criteria OR
- At the waiting list for liver transplantation OR
- Daily alcohol intake above 20 g and 30 g for women and men respectively OR
- Known hepatitis A, B or C or hepatocellular carcinoma or other known liver disease OR
- Dialysis therapy OR
- Pregnancy OR
- Weight \> 130 kg OR
- Implanted pacemaker
Exclusion
Key Trial Info
Start Date :
May 6 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 23 2021
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT03826381
Start Date
May 6 2019
End Date
June 23 2021
Last Update
September 1 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Nephrology
Copenhagen, Denmark, 2100